Apixaban not superior to aspirin in reducing risk of recurrent stroke | Top Vip News
[ad_1] Hooman Kamel, MD Credit: LinkedIn Results from the ARCADIA randomized clinical trial demonstrated that apixaban did not significantly reduce the risk of recurrent stroke compared with aspirin among patients with cryptogenic stroke and evidence of atrial heart disease without atrial fibrillation (AF).1 More than 1,000 participants in the multicenter, double-blind phase 3 clinical trial … Read more